Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Salivary secretion in children after fractionated or single-dose TBI

Bone Marrow Transplantation volume 47, pages 404–410 (2012)Cite this article

Abstract

The incidence of long-term oral complications after hematopoietic SCT (HSCT) varies between 60 and 100%. The aim of this study was to compare the salivary secretion rate and the contribution of known risk factors for a low salivary secretion rate 1 year after HSCT in children conditioned with fractionated TBI (fTBI) and in children conditioned with single-dose TBI (sTBI). The study involved 44 patients, 27 conditioned with sTBI and 17 conditioned with fTBI. The unstimulated and stimulated salivary secretion rates (USSRs and SSSRs) were estimated before HSCT and at 1-year follow-up. Risk factors that may have influenced the salivary secretion rate were recorded. An SSSR of ⩽0.5 mL/min and a USSR of ⩽0.1 mL/min were chosen as cut-off points for salivary dysfunction. The median reduction in stimulated salivary flow 1 year after HSCT was 56% in the sTBI group and 12% in the fTBI group (P=0.003). The median reduction in unstimulated salivary flow 1 year after HSCT was 74% in the sTBI group and 33% in the fTBI group (P=0.003). In the multivariate model, a significant correlation between both sTBI (odds ratio (OR)=6.49, 95% confidence interval (CI)=1.40–30, P=0.014) and seropositivity of the recipient for 3–4 herpesviruses (OR=6.57, 95% CI=1.26–34, P=0.021) and a low stimulated salivary secretion rate (<0.5 mL/min) was found 1 year after HSCT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Thomas ED, Fefer A, Buckner CD, Storb R . Current status of bone marrow transplantation for aplastic anemia and acute leukemia. Blood 1977; 49: 671–681.

    CAS  PubMed  Google Scholar 

  2. Barrett AJ, Horowitz MM, Gale RP, Biggs JC, Camitta BM, Dicke KA et al. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood 1989; 74: 862–871.

    CAS  PubMed  Google Scholar 

  3. Ringdén O, Le Blanc K . Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives. APMIS 2005; 113: 813–830.

    Article  PubMed  Google Scholar 

  4. Ringdén O, Hermans J, Labopin M, Apperley J, Gorin NC, Gratwohl A . The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). Leuk Lymphoma 1996; 24: 71–79.

    Article  PubMed  Google Scholar 

  5. Ringdén O, Deeg HJ (eds.) Clinical Spectrum of Graft-Versus-Host Disease, 2nd edn. Marcel Dekker Inc: New York, 1996.

    Google Scholar 

  6. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Avigdor A, Ben-Bassat I . Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006; 20: 322–328.

    Article  CAS  PubMed  Google Scholar 

  7. Alyea E, Kim H, Ho V, Cutler C, DeAngelo D, Stone R . Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006; 12: 1047–1055.

    Article  PubMed  Google Scholar 

  8. Ringdén O . Allogeneic bone marrow transplantation for hematological malignancies-controversies and recent advances. Acta Oncol 1997; 36: 549–564.

    Article  PubMed  Google Scholar 

  9. Davies S, Ramsay N, Klein J, Weisdorf D, Bolwell B, Cahn J-Y et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 340–347.

    Article  CAS  PubMed  Google Scholar 

  10. Deeg HJ . Bone marrow transplantation: a review of delayed complications. Br J Haematol 1984; 57: 185–208.

    Article  CAS  PubMed  Google Scholar 

  11. Sanders JE . The impact of marrow transplant preparative regimens on subsequent growth and development. Semin Haematol 1991; 28: 244–249.

    CAS  Google Scholar 

  12. Ringdén O . Bone marrow transplantation using unrelated donors for haematological malignancies. Med Oncol 1997; 14: 11–22.

    Article  PubMed  Google Scholar 

  13. Clift R, Buckner D, Appelbaum F, Bearman S, Petersen F, Fisher L et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomised trial of two irradiation regimens. Blood 1990; 76: 1867–1871.

    CAS  PubMed  Google Scholar 

  14. Epstein J, Haveman C, Huber M, Peterson D, Plemons J, Redding S et al. Oral health in cancer therapy. A guide for health care professionals. In: Rankin V, Gones D, Redding S (eds). Consensus Development Conference on Oral Health in Cancer Therapy by the Dental Oncology Education Programme, 3rd edn. Monographs 2008. Available from: http://www.nidcr.nih.gov.

  15. Schubert M, Appelbaum F, Peterson D, Lloid M . Oral complications. In: Blume KG, Forman SJ (eds). Thomas’ Hematopoetic Cell Transplantation, 3rd edn. Blackwell Science Inc: Malden, MA, 2004, pp 911–928.

    Google Scholar 

  16. Dahllöf G, Heimdahl A, Bolme P, Lönnqvist B, Ringdén O . Oral condition in children treated with bone marrow transplantation. Bone Marrow Transplant 1988; 3: 43–51.

    PubMed  Google Scholar 

  17. Dahllöf G, Krekmanova L, Kopp S, Borgström B, Forsberg CM, Ringdén O . Craniomandibular dysfunction in children treated with total-body irradiation and bone marrow transplantation. Acta Odontol Scand 1994; 52: 99–105.

    Article  PubMed  Google Scholar 

  18. Berkowitz RJ, Strandfjord S, Jones P, Hughes C, Barsetti J, Gordon EM et al. Stomatologic complications of bone marrow transplantation in a pediatric population. Pediatr Dent 1987; 9: 105–109.

    CAS  PubMed  Google Scholar 

  19. Näsman M, Björk O, Söderhäll S, Ringdén O, Dahllöf G . Disturbances in the oral cavity in pediatrictic long-term survivors after different forms of antineoplastic therapy. Pediatr Dent 1994; 16: 217–223.

    PubMed  Google Scholar 

  20. Dahllöf G, Bågesund M, Ringdén O . Impact of conditioning regimens on salivary function, caries associated microorganisms and dental caries in children after bone marrow transplantation. A 4-year longitudinal study. Bone Marrow Transplant 1997; 20: 479–483.

    Article  PubMed  Google Scholar 

  21. Dahllöf G, Bågesund M, Remberger M, Ringdén O . Risk factors for salivary dysfunction in children 1 year after bone marrow transplantation. Oral Oncol 1997; 33: 327–331.

    Article  PubMed  Google Scholar 

  22. Down JD, Tarbell NJ, Thames HD, Mauch PM . Syngeneic and allogeneic bone marrow engraftment after total body irradiation: dependence on dose, dose rate and fractionation. Blood 1991; 77: 661–669.

    CAS  PubMed  Google Scholar 

  23. Adkins DR, Dipersio JF . Total body irradiation before an allogeneic stem cell transplantation: is there a magic dose? Curr Opin Hematol 2008; 15: 555–560.

    Article  PubMed  Google Scholar 

  24. Girinsky T, Benhamou E, Bourhis JH, Dhermain F, Guilliot-Valls D, Ganansia V et al. Prospective randomized comparison of single-dose versus hyperfractionated total body irradiation in patients with hematologic malignancies. J Clin Oncol 2000; 18: 981–986.

    Article  CAS  PubMed  Google Scholar 

  25. Aristei C, Allesandro M, Santucci A, Aversa F, Tabillo A, Carotti A et al. Cataracts in patients receiving stem cell transplantation after conditioning with total body irradiation. Bone Marrow Transplant 2002; 29: 503–507.

    Article  CAS  PubMed  Google Scholar 

  26. Cosset JM, Girinsky T, Malaise E, Chaillet MP, Dutreix J . Clinical basis for TBI fractionation. Radiother Oncol Suppl 11990; 18 (Suppl 1): 60–67.

    Google Scholar 

  27. Oya N, Sasai K, Tachiiri S, Sakamoto T, Nagata Y, Okada T et al. Influence of radiation dose rate and lung dose on interstitial pneumonitis after fractionated total body irradiation: acute parotitis may predict interstitial pneumonitis. Int J Hematol 2006; 83: 86–91.

    Article  PubMed  Google Scholar 

  28. Jensen SB, Pedersen ML, Vissink A, Andersen E, Brown CG, Davies AN et al. A systematic review of salivary hypofunction and xerestomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 2010; 18: 1061–1079.

    Article  CAS  PubMed  Google Scholar 

  29. Jen YM, Lin YC, Wang YB, Wu DM . Dramatic prolonged decrease of whole salivary secretion in nasopharyngeal carcinoma patients treated with radiotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101: 322–327.

    Article  PubMed  Google Scholar 

  30. Buchali A, Feyer P, Groll J, Massenkeil G, Arnold R, Budach V . Immediate toxicity during fractionated total body irradiation as conditioning for bone marrow transplantation. Radiother Oncol 2000; 54: 157–162.

    Article  CAS  PubMed  Google Scholar 

  31. Bågesund M, Winiarski J, Dahllöf G . Subjective xerostomia in long-term surviving children and adolescents after pediatric bone marrow transplantation. Transplantation 2000; 69: 822–826.

    Article  PubMed  Google Scholar 

  32. Taylor SE, Miller EG . Preemptive pharmacological intervention in radiation-induced salivary dysfunction. Proc Soc Exp Biol Med 1999; 221: 14–26.

    Article  CAS  PubMed  Google Scholar 

  33. Kashima HK, Kirkham WR, Andrews JR . Postirradiation sialodenitis. Am J Roentgenol Radium Ther Nucl Med 1965; 94: 271–291.

    Google Scholar 

  34. Yagil C, Michaeli Y, Zajicek G . Compensatory proliferative response of the rat submandibular salivary gland to unilateral extirpation. Virchows Arch B Cell Pathol Incl Mol Pathol 1985; 49: 83–91.

    Article  CAS  PubMed  Google Scholar 

  35. Stephens CL, Schultheiss TE, Price RE, Ang KK, Peters LJ . Radiation apoptosis of serous acinar cells of salivary and lacrimal glands. Cancer 1991; 67: 1539–1543.

    Article  CAS  PubMed  Google Scholar 

  36. Wollf A, Limor ZP, Kaplan I . Major salivary gland output differs between users and non-users of specific medication categories. Gerodontology 2008; 25: 210–216.

    Article  Google Scholar 

  37. Shillitoe EJ, Daniels TE, Whitcher JP, Strand CV, Talal N, Greenspan JS . Antibody to cytomegalovirus in patients with Sjögren's syndrome. Arthritis Rheum 1982; 25: 260–265.

    Article  CAS  PubMed  Google Scholar 

  38. Fox RI, Luppi M, Pisa P, Kang HI . Potential role of Epstein-Barr virus in Sjögren's syndrome and rheumatoid arthritis. J Rheumatol Suppl 1992; 32: 18–24.

    CAS  PubMed  Google Scholar 

  39. Yamaoka K, Miyasaka N, Yamamoto K . Possible involvement of Epstein-Barr virus polyclonal B cell activation in Sjögrens syndrome. Arthritis Rheum 1988; 31: 1014–1021.

    Article  CAS  PubMed  Google Scholar 

  40. Fox JD, Briggs M, Ward P, Tedder R . Human herpesvirus 6 in salivary glands. Lancet 1990; 336: 590–593.

    Article  CAS  PubMed  Google Scholar 

  41. Imanguli M, Atkinson J, Mitchell S, Avila D, Bishop R, Cowen E et al. Salivary gland involvement in chronic graft-versus-host disease: prevalence, clinical significance, and recommendations for evaluation. Biol Blood Marrow Transpl 2010; 16: 1362–1369.

    Article  Google Scholar 

  42. Heimdahl A, Johnson G, Danielsson KH, Lönnqvist B, Ringdén O . Oral condition of patients with leukaemia and aplastic anemia. Oral Surg Oral Med Oral Pathol 1985; 60: 498–504.

    Article  CAS  PubMed  Google Scholar 

  43. Ringdén O, Deeg HJ . Clinical spectrum of graft-versus-host disease. In: Ferrara JLM, Deeg HJ, Burakoff S (eds). Graft vs Host Disease, 2nd edn. Marcel Dekker, Inc: New York, 1996, pp 525–559.

    Google Scholar 

Download references

Acknowledgements

This study was supported by grants from the Swedish Dental Society, Swedish Medical Society, Swedish Childhood Cancer Foundation and Karolinska Institute.

Author information

Authors and Affiliations

  1. Department of Dental Medicine, Division of Oral and Maxillofacial Surgery, Karolinska Institute, Huddinge, Sweden

    K Garming Legert & A Heimdahl

  2. Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Huddinge, Sweden

    M Remberger & O Ringdèn

  3. Division of Pediatric Dentistry, Department of Dental Medicine, Karolinska Institute, Huddinge, Sweden

    G Dahllöf

Authors
  1. K Garming Legert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Remberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O Ringdèn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Heimdahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Dahllöf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K Garming Legert.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Legert, K., Remberger, M., Ringdèn, O. et al. Salivary secretion in children after fractionated or single-dose TBI. Bone Marrow Transplant 47, 404–410 (2012). https://doi.org/10.1038/bmt.2011.96

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.96

Keywords

This article is cited by

Search

Advanced search

Quick links